BACKGROUND & AIMS: Portal vein embolization (PVE) is a standard technique for patients not amenable to liver resection due to small future liver remnant ratio (FLR). Radiation lobectomy (RL) with (90)Y-loaded microspheres (Y90) is hypothesized to induce comparable volumetric changes in liver lobes, while potentially controlling the liver tumor and limiting tumor progression in the untreated lobe. We aimed at testing this concept by performing a comprehensive time-dependent analysis of liver volumes following radioembolization. METHODS: 83 patients with right unilobar disease with hepatocellular carcinoma (HCC; N=67), cholangiocarcinoma (CC; N=8) or colorectal cancer (CRC; N=8) were treated by Y90 RL. The total liver volume, lobar (parenchymal) and tumor volumes, FLR and percentage of FLR hypertrophy from baseline (%FLR hypertrophy) were assessed on pre- and post-Y90 CT/MRI scans in a dynamic fashion. RESULTS: Right lobe atrophy (p=0.003), left lobe hypertrophy (p<0.001), and FLR hypertrophy (p<0.001) were observed 1 month after Y90 and this was consistent at all follow-up time points. Median %FLR hypertrophy reached 45% (5-186) after 9 months (p<0.001). The median maximal %FLR hypertrophy was 26% (-14 → 86). Portal vein thrombosis was correlated to %FLR hypertrophy (p=0.02). Median Child-Pugh score worsening (6 → 7) was seen at 1 to 3 months (p=0.03) and 3 to 6 months (p=0.05) after treatment. Five patients underwent successful right lobectomy (HCC N=3, CRC N=1, CC N=1) and 6 HCCs were transplanted. CONCLUSIONS: Radiation lobectomy by Y90 is a safe and effective technique to hypertrophy the FLR. Volumetric changes are comparable (albeit slightly slower) to PVE while the right lobe tumor is treated synchronously. This novel technique is of particular interest in the bridge-to-resection setting.
BACKGROUND & AIMS: Portal vein embolization (PVE) is a standard technique for patients not amenable to liver resection due to small future liver remnant ratio (FLR). Radiation lobectomy (RL) with (90)Y-loaded microspheres (Y90) is hypothesized to induce comparable volumetric changes in liver lobes, while potentially controlling the liver tumor and limiting tumor progression in the untreated lobe. We aimed at testing this concept by performing a comprehensive time-dependent analysis of liver volumes following radioembolization. METHODS: 83 patients with right unilobar disease with hepatocellular carcinoma (HCC; N=67), cholangiocarcinoma (CC; N=8) or colorectal cancer (CRC; N=8) were treated by Y90 RL. The total liver volume, lobar (parenchymal) and tumor volumes, FLR and percentage of FLR hypertrophy from baseline (%FLR hypertrophy) were assessed on pre- and post-Y90 CT/MRI scans in a dynamic fashion. RESULTS: Right lobe atrophy (p=0.003), left lobe hypertrophy (p<0.001), and FLR hypertrophy (p<0.001) were observed 1 month after Y90 and this was consistent at all follow-up time points. Median %FLR hypertrophy reached 45% (5-186) after 9 months (p<0.001). The median maximal %FLR hypertrophy was 26% (-14 → 86). Portal vein thrombosis was correlated to %FLR hypertrophy (p=0.02). Median Child-Pugh score worsening (6 → 7) was seen at 1 to 3 months (p=0.03) and 3 to 6 months (p=0.05) after treatment. Five patients underwent successful right lobectomy (HCC N=3, CRC N=1, CC N=1) and 6 HCCs were transplanted. CONCLUSIONS: Radiation lobectomy by Y90 is a safe and effective technique to hypertrophy the FLR. Volumetric changes are comparable (albeit slightly slower) to PVE while the right lobe tumor is treated synchronously. This novel technique is of particular interest in the bridge-to-resection setting.
Authors: David C Madoff; Marshall E Hicks; Jean-Nicolas Vauthey; Chusilp Charnsangavej; Frank A Morello; Kamran Ahrar; Michael J Wallace; Sanjay Gupta Journal: Radiographics Date: 2002 Sep-Oct Impact factor: 5.333
Authors: Lisette T Hoekstra; Krijn P van Lienden; Joanne Verheij; Chris M van der Loos; Michal Heger; Thomas M van Gulik Journal: J Surg Res Date: 2012-11-06 Impact factor: 2.192
Authors: Lars Fischer; Matthias Thorn; Jan O Neumann; Max Schöbinger; Tobias Heimann; Lars Grenacher; Hans P Meinzer; Helmut Friess; Markus W Büchler Journal: Eur J Radiol Date: 2005-02 Impact factor: 3.528
Authors: Lisette T Hoekstra; Krijn P van Lienden; Ageeth Doets; Olivier R C Busch; Dirk J Gouma; Thomas M van Gulik Journal: Ann Surg Date: 2012-11 Impact factor: 12.969
Authors: Honsoul Kim; Mi-Suk Park; Young Nyun Park; Hyunki Kim; Kyung Sik Kim; Jin Sub Choi; Sang Hoon Ahn; Kwang-Hyub Han; Myeong-Jin Kim; Ki Whang Kim Journal: Yonsei Med J Date: 2009-12-18 Impact factor: 2.759
Authors: Victor M Zaydfudim; Neeta Vachharajani; Goran B Klintmalm; William R Jarnagin; Alan W Hemming; Maria B Majella Doyle; Keith M Cavaness; William C Chapman; David M Nagorney Journal: Ann Surg Date: 2016-10 Impact factor: 12.969
Authors: Jehan L Shah; Ivan R Zendejas-Ruiz; Linday M Thornton; Brian S Geller; Joseph R Grajo; Amy Collinsworth; Thomas J George; Beau Toskich Journal: J Gastrointest Oncol Date: 2017-06
Authors: Sandra van der Velden; Manon N G J A Braat; Tim A Labeur; Mike V Scholten; Otto M van Delden; Roelof J Bennink; Hugo W A M de Jong; Marnix G E H Lam Journal: J Nucl Med Date: 2019-04-06 Impact factor: 10.057
Authors: Alexander Villalobos; Mohamed M Soliman; Bill S Majdalany; David M Schuster; James Galt; Zachary L Bercu; Nima Kokabi Journal: Semin Intervent Radiol Date: 2020-12-11 Impact factor: 1.513
Authors: Riad Salem; Andrew C Gordon; Samdeep Mouli; Ryan Hickey; Joseph Kallini; Ahmed Gabr; Mary F Mulcahy; Talia Baker; Michael Abecassis; Frank H Miller; Vahid Yaghmai; Kent Sato; Kush Desai; Bartley Thornburg; Al B Benson; Alfred Rademaker; Daniel Ganger; Laura Kulik; Robert J Lewandowski Journal: Gastroenterology Date: 2016-08-27 Impact factor: 22.682